Analysts Maintain Certara Price Target as Pharma Sector Recovery and New Developments Drive Outlook

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

08 Jun 25

Updated

04 Dec 25

Views

132

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-23.3%

7D

-4.7%

Loading

1Y

-23.3%

7D

-4.7%

You can edit this narrative until Dec 5 7:10 AM. Then, changes will post as Updates.

Author's Valuation

US$13.2133.8% undervalued

AnalystConsensusTarget Fair Value

Shared on 04 Dec 25

Fair value Decreased 2.16%

CERT: Shares Will Benefit From Biosimulation Leadership As Pharma Rebound Emerges

The analyst price target for Certara has been modestly reduced from $13.50 to about $13.21, as analysts balance near term headwinds in services bookings with growing confidence in the company’s leadership in biosimulation and its longer term role in modernizing drug development. Analyst Commentary Recent research updates reflect a generally constructive but selective stance on Certara, with views splitting between enthusiasm for its strategic position in biosimulation and caution around execution risk and near term bookings softness.

Shared on 20 Nov 25

Fair value Decreased 8.47%

CERT: Shares Will Benefit From Pharma Rebound And Drug Development Modernization

Analysts have reduced Certara's fair value price target from $14.75 to $13.50, citing revised growth expectations, softer profit margins, and a need for clearer evidence of traction in core initiatives. Analyst Commentary Recent analyst research highlights a range of perspectives on Certara, with differing views on both its near-term prospects and longer-term potential within the drug development sector.

Shared on 06 Nov 25

CERT: Shares Poised To Gain From Pharma And Biotech Sector Rebound Ahead

Analyst Price Target Update for Certara Analysts have maintained their price target for Certara at $14.75 per share, citing the company's strong positioning in the anticipated pharma and biotech rebound as well as an attractive current valuation relative to its long-term prospects. Analyst Commentary Analyst perspectives on Certara highlight a mix of optimism and caution as the company positions itself within a strengthening pharmaceutical and biotechnology sector.

Shared on 23 Oct 25

Analysts have maintained their price target for Certara at $14.75, citing the company’s positioning at the center of a recovering pharma and biotech sector as a key reason for their continued positive outlook. Analyst Commentary Bullish Takeaways Bullish analysts highlight Certara's central position in the anticipated rebound of the pharma and biotech sectors.

Shared on 08 Oct 25

Fair value Increased 4.53%

Certara's analyst price target has increased from $14.11 to $14.75. This change reflects analysts' optimism about the company's strategic position in the pharma sector and its potential to benefit from growing R&D investment trends.

Shared on 08 Aug 25

Fair value Decreased 2.31%

The slight downward revision in Certara’s price target reflects a modest reduction in its future P/E ratio, while revenue growth expectations remain essentially unchanged, resulting in a new consensus price target of $14.11. What's in the News Certara reiterated full-year 2025 revenue guidance of $415 million to $425 million.

AnalystConsensusTarget Fair Value

US$13.21

33.8% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

6.62%

Healthtech revenue growth rate

12.68%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

8.79%

Calculation

US$32.99m

Earnings '28

x

79.20x

PE Ratio '28

=

US$2.61b

Market Cap '28

US$2.61b

Market Cap '28

/

154.15m

No. shares '28

=

US$16.95

Share Price '28

US$16.95 Share Price '28

Discounted to 2025 @ 8.70% p.a.

=

US$13.20

Fair Value '25